Literature DB >> 25323624

Negative versus positive allosteric modulation of metabotropic glutamate receptors (mGluR5): indices for potential pro-cognitive drug properties based on EEG network oscillations and sleep-wake organization in rats.

A Ahnaou1, X Langlois, T Steckler, J M Bartolome-Nebreda, W H I M Drinkenburg.   

Abstract

RATIONALE: Evidence is emerging that positive and negative modulation of the metabotropic glutamate (mGluR5) receptors has the potential for treating cognitive deficits and neuroprotection associated with psychiatric and neurodegenerative diseases, respectively. Sleep and synchronisation of disparate neuronal networks are critically involved in neuronal plasticity, and disturbance in vigilance states and cortical network connectivity contribute significantly to cognitive deficits described in schizophrenia and Alzheimer's disease. Here, we examined the circadian changes of mGluR5 density and the functional response to modulation of mGluR5 signaling.
METHODS: The current study carried out in Sprague-Dawley rats quantified the density of mGluR5 across the light-dark cycle with autoradiography. The central activity of mGluR5 negative allosteric modulators (2-methyl-6-(phenylethynyl)pyridine (MPEP) and [(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) and positive allosteric modulators (S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-methanone (ADX47273) and (7S)-3-tert-butyl-7-[3-(4-fluoro-phenyl)-1,2,4-oxadiazol-5-yl]-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridine (LSN2814617) was examined on sleep-wake architecture. The functional effect of mGluR5 modulation on cortical networks communication was described in freely moving animals.
RESULTS: The density of mGluR5 in the striatal, cortical, hippocampal and thalamic structures was unchanged across the light-dark cycle. Allosteric blockade of mGluR5 consistently consolidated deep sleep, enhanced sleep efficiency and elicited prominent functional coherent network activity in slow theta and gamma oscillations. However, allosteric activation of mGluR5 increased waking, decreased deep sleep and reduced functional network connectivity following the activation of slow alpha oscillatory activity.
CONCLUSION: This functional study differentiates the pharmacology of allosteric blockade of mGluR5 from that of allosteric activation and suggests that mGluR5 blockade enhances sleep and facilitates oscillatory network connectivity, both processes being known to have relevance in cognition processes.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25323624     DOI: 10.1007/s00213-014-3746-4

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  92 in total

1.  EEG-power and -coherence changes in a unimodal and a crossmodal working memory task with visual and kinesthetic stimuli.

Authors:  A Seemüller; E M Müller; F Rösler
Journal:  Int J Psychophysiol       Date:  2011-11-10       Impact factor: 2.997

2.  Functional coupling between frontal and parietal lobes during recognition memory.

Authors:  Christopher Summerfield; Jennifer A Mangels
Journal:  Neuroreport       Date:  2005-02-08       Impact factor: 1.837

Review 3.  Neuronal coherence during selective attentional processing and sensory-motor integration.

Authors:  Thilo Womelsdorf; Pascal Fries
Journal:  J Physiol Paris       Date:  2007-01-17

4.  Mice lacking metabotropic glutamate receptor 5 show impaired learning and reduced CA1 long-term potentiation (LTP) but normal CA3 LTP.

Authors:  Y M Lu; Z Jia; C Janus; J T Henderson; R Gerlai; J M Wojtowicz; J C Roder
Journal:  J Neurosci       Date:  1997-07-01       Impact factor: 6.167

5.  Relative contributions of intracortical and thalamo-cortical processes in the generation of alpha rhythms, revealed by partial coherence analysis.

Authors:  F H Lopes da Silva; J E Vos; J Mooibroek; A Van Rotterdam
Journal:  Electroencephalogr Clin Neurophysiol       Date:  1980-12

6.  Treatment of anxiety using fenobam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebo-controlled study.

Authors:  J C Pecknold; D J McClure; L Appeltauer; L Wrzesinski; T Allan
Journal:  J Clin Psychopharmacol       Date:  1982-04       Impact factor: 3.153

7.  Differential plasma membrane distribution of metabotropic glutamate receptors mGluR1 alpha, mGluR2 and mGluR5, relative to neurotransmitter release sites.

Authors:  R Luján; J D Roberts; R Shigemoto; H Ohishi; P Somogyi
Journal:  J Chem Neuroanat       Date:  1997-10       Impact factor: 3.052

8.  Homer-dependent cell surface expression of metabotropic glutamate receptor type 5 in neurons.

Authors:  Fabrice Ango; David Robbe; Jian Cheng Tu; Bo Xiao; Paul F Worley; Jean-Philippe Pin; Joël Bockaert; Laurent Fagni
Journal:  Mol Cell Neurosci       Date:  2002-06       Impact factor: 4.314

Review 9.  Human gamma-band activity: a review on cognitive and behavioral correlates and network models.

Authors:  Christoph S Herrmann; Ingo Fründ; Daniel Lenz
Journal:  Neurosci Biobehav Rev       Date:  2009-09-08       Impact factor: 8.989

10.  The effect of an mGluR5 inhibitor on procedural memory and avoidance discrimination impairments in Fmr1 KO mice.

Authors:  M F Vinueza Veloz; R A M Buijsen; R Willemsen; A Cupido; L W J Bosman; S K E Koekkoek; J W Potters; B A Oostra; C I De Zeeuw
Journal:  Genes Brain Behav       Date:  2012-01-19       Impact factor: 3.449

View more
  9 in total

1.  Homer1a drives homeostatic scaling-down of excitatory synapses during sleep.

Authors:  Graham H Diering; Raja S Nirujogi; Richard H Roth; Paul F Worley; Akhilesh Pandey; Richard L Huganir
Journal:  Science       Date:  2017-02-02       Impact factor: 47.728

2.  Alterations in sleep, sleep spindle, and EEG power in mGluR5 knockout mice.

Authors:  David D Aguilar; Robert E Strecker; Radhika Basheer; James M McNally
Journal:  J Neurophysiol       Date:  2019-11-20       Impact factor: 2.714

3.  Dissociable effects of mGluR5 allosteric modulation on distinct forms of impulsivity in rats: interaction with NMDA receptor antagonism.

Authors:  Sarah N Isherwood; Anton Pekcec; Janet R Nicholson; Trevor W Robbins; Jeffrey W Dalley
Journal:  Psychopharmacology (Berl)       Date:  2015-06-12       Impact factor: 4.530

4.  Distinct pro-vigilant profile induced in rats by the mGluR5 potentiator LSN2814617.

Authors:  Sally Loomis; Andrew McCarthy; Christopher Baxter; Daniel O Kellett; Dale M Edgar; Mark Tricklebank; Gary Gilmour
Journal:  Psychopharmacology (Berl)       Date:  2015-04-24       Impact factor: 4.530

5.  Ketamine: differential neurophysiological dynamics in functional networks in the rat brain.

Authors:  A Ahnaou; H Huysmans; R Biermans; N V Manyakov; W H I M Drinkenburg
Journal:  Transl Psychiatry       Date:  2017-09-19       Impact factor: 6.222

Review 6.  Homer1a and mGluR1/5 Signaling in Homeostatic Sleep Drive and Output.

Authors:  Shenée C Martin; Sarah K Monroe; Graham H Diering
Journal:  Yale J Biol Med       Date:  2019-03-25

7.  Sleep-Wake Rhythm and Oscillatory Pattern Analysis in a Multiple Hit Schizophrenia Rat Model (Wisket).

Authors:  Leatitia Gabriella Adlan; Mátyás Csordás-Nagy; Balázs Bodosi; György Kalmár; László G Nyúl; Attila Nagy; Gabriella Kekesi; Alexandra Büki; Gyongyi Horvath
Journal:  Front Behav Neurosci       Date:  2022-01-28       Impact factor: 3.558

8.  Cerebral mGluR5 availability contributes to elevated sleep need and behavioral adjustment after sleep deprivation.

Authors:  Sebastian C Holst; Alexandra Sousek; Katharina Hefti; Sohrab Saberi-Moghadam; Alfred Buck; Simon M Ametamey; Milan Scheidegger; Paul Franken; Anke Henning; Erich Seifritz; Mehdi Tafti; Hans-Peter Landolt
Journal:  Elife       Date:  2017-10-05       Impact factor: 8.140

9.  Partial mGlu5 Negative Allosteric Modulator M-5MPEP Demonstrates Antidepressant-Like Effects on Sleep Without Affecting Cognition or Quantitative EEG.

Authors:  Kimberly M Holter; Alex D Lekander; Christina M LaValley; Elizabeth G Bedingham; Bethany E Pierce; L Paul Sands; Craig W Lindsley; Carrie K Jones; Robert W Gould
Journal:  Front Neurosci       Date:  2021-07-02       Impact factor: 4.677

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.